CA2505923A1 - Antibody-or neutrophil-mediated ozone generation - Google Patents

Info

Publication number

CA2505923A1

CA2505923A1 CA002505923A CA2505923A CA2505923A1 CA 2505923 A1 CA2505923 A1 CA 2505923A1 CA 002505923 A CA002505923 A CA 002505923A CA 2505923 A CA2505923 A CA 2505923A CA 2505923 A1 CA2505923 A1 CA 2505923A1

Authority

CA

Canada

Prior art keywords

statement

antibody

oxygen species

reactive oxygen

sample

Prior art date

2002-11-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 210000000440 neutrophil Anatomy 0.000 title claims abstract description 116
• CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 title claims description 52
• 230000001404 mediated effect Effects 0.000 title description 36
• 238000000034 method Methods 0.000 claims abstract description 161
• 239000003642 reactive oxygen metabolite Substances 0.000 claims abstract description 101
• 239000000523 sample Substances 0.000 claims description 127
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 106
• 239000000126 substance Substances 0.000 claims description 101
• KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 claims description 49
• 229960003988 indigo carmine Drugs 0.000 claims description 49
• 239000004179 indigotine Substances 0.000 claims description 49
• 235000012738 indigotine Nutrition 0.000 claims description 49
• 230000003647 oxidation Effects 0.000 claims description 48
• 238000007254 oxidation reaction Methods 0.000 claims description 48
• 230000000694 effects Effects 0.000 claims description 41
• 239000001301 oxygen Substances 0.000 claims description 40
• 229910052760 oxygen Inorganic materials 0.000 claims description 40
• 241000124008 Mammalia Species 0.000 claims description 26
• IRQWEODKXLDORP-UHFFFAOYSA-N 4-ethenylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=C)C=C1 IRQWEODKXLDORP-UHFFFAOYSA-N 0.000 claims description 21
• 239000003795 chemical substances by application Substances 0.000 claims description 20
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 19
• VWXZFDWVWMQRQR-UHFFFAOYSA-N 3-ethenylbenzoic acid Chemical group OC(=O)C1=CC=CC(C=C)=C1 VWXZFDWVWMQRQR-UHFFFAOYSA-N 0.000 claims description 16
• 210000001519 tissue Anatomy 0.000 claims description 15
• 230000028993 immune response Effects 0.000 claims description 14
• 238000012360 testing method Methods 0.000 claims description 13
• 230000028709 inflammatory response Effects 0.000 claims description 12
• 238000004949 mass spectrometry Methods 0.000 claims description 11
• 210000001124 body fluid Anatomy 0.000 claims description 10
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
• 238000004128 high performance liquid chromatography Methods 0.000 claims description 10
• 238000004811 liquid chromatography Methods 0.000 claims description 10
• 238000002798 spectrophotometry method Methods 0.000 claims description 10
• TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 9
• 239000007789 gas Substances 0.000 claims description 8
• OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 claims description 8
• 230000003213 activating effect Effects 0.000 claims description 7
• 210000004369 blood Anatomy 0.000 claims description 6
• 239000008280 blood Substances 0.000 claims description 6
• 239000013626 chemical specie Substances 0.000 claims description 6
• 238000004611 spectroscopical analysis Methods 0.000 claims description 6
• PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 5
• 150000001336 alkenes Chemical class 0.000 claims description 5
• 235000012000 cholesterol Nutrition 0.000 claims description 5
• 238000000099 in vitro assay Methods 0.000 claims description 5
• PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 5
• 235000021286 stilbenes Nutrition 0.000 claims description 5
• 210000002751 lymph Anatomy 0.000 claims description 4
• 210000001179 synovial fluid Anatomy 0.000 claims description 4
• 210000003097 mucus Anatomy 0.000 claims description 3
• 210000002381 plasma Anatomy 0.000 claims description 3
• 210000003296 saliva Anatomy 0.000 claims description 3
• 210000002966 serum Anatomy 0.000 claims description 3
• 210000001138 tear Anatomy 0.000 claims description 3
• 210000002700 urine Anatomy 0.000 claims description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 103
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 90
• 239000002953 phosphate buffered saline Substances 0.000 description 90
• 238000004519 manufacturing process Methods 0.000 description 74
• 210000004027 cell Anatomy 0.000 description 70
• 102000004169 proteins and genes Human genes 0.000 description 67
• 108090000623 proteins and genes Proteins 0.000 description 67
• 235000018102 proteins Nutrition 0.000 description 66
• 239000000427 antigen Substances 0.000 description 63
• 239000000243 solution Substances 0.000 description 59
• 229910001868 water Inorganic materials 0.000 description 59
• 108091007433 antigens Proteins 0.000 description 57
• 102000036639 antigens Human genes 0.000 description 57
• 239000000203 mixture Substances 0.000 description 57
• UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 56
• 238000003556 assay Methods 0.000 description 54
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
• 241000699666 Mus <mouse, genus> Species 0.000 description 48
• 241000588724 Escherichia coli Species 0.000 description 46
• 238000002474 experimental method Methods 0.000 description 43
• 238000006243 chemical reaction Methods 0.000 description 42
• 230000015572 biosynthetic process Effects 0.000 description 41
• 230000008569 process Effects 0.000 description 38
• 241001529936 Murinae Species 0.000 description 35
• 102000016938 Catalase Human genes 0.000 description 31
• 108010053835 Catalase Proteins 0.000 description 31
• 230000000844 anti-bacterial effect Effects 0.000 description 31
• 108060003951 Immunoglobulin Proteins 0.000 description 30
• 125000004429 atom Chemical group 0.000 description 30
• 102000018358 immunoglobulin Human genes 0.000 description 30
• 241000282414 Homo sapiens Species 0.000 description 29
• 241001494479 Pecora Species 0.000 description 29
• 239000008363 phosphate buffer Substances 0.000 description 29
• 230000004913 activation Effects 0.000 description 25
• 239000007800 oxidant agent Substances 0.000 description 24
• 239000000047 product Substances 0.000 description 24
• 241000894006 Bacteria Species 0.000 description 22
• 238000001514 detection method Methods 0.000 description 21
• 238000010348 incorporation Methods 0.000 description 21
• -1 tetrahydrocanabinol Chemical compound 0.000 description 21
• 235000002639 sodium chloride Nutrition 0.000 description 20
• 206010061218 Inflammation Diseases 0.000 description 19
• 230000004054 inflammatory process Effects 0.000 description 19
• 230000002147 killing effect Effects 0.000 description 19
• 108090000765 processed proteins & peptides Proteins 0.000 description 19
• 230000001590 oxidative effect Effects 0.000 description 18
• FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 18
• QPBDAHXYPMQZTA-UHFFFAOYSA-N 2,3-dioxoindole-1-sulfonic acid Chemical compound C1=CC=C2N(S(=O)(=O)O)C(=O)C(=O)C2=C1 QPBDAHXYPMQZTA-UHFFFAOYSA-N 0.000 description 17
• 239000012634 fragment Substances 0.000 description 17
• 238000001819 mass spectrum Methods 0.000 description 17
• 230000009467 reduction Effects 0.000 description 17
• 229910052724 xenon Inorganic materials 0.000 description 17
• 229910001882 dioxygen Inorganic materials 0.000 description 16
• 208000015181 infectious disease Diseases 0.000 description 16
• 230000007246 mechanism Effects 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 15
• 230000001580 bacterial effect Effects 0.000 description 15
• 239000013078 crystal Substances 0.000 description 15
• 125000004122 cyclic group Chemical group 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 239000007788 liquid Substances 0.000 description 15
• 239000000463 material Substances 0.000 description 15
• 239000000758 substrate Substances 0.000 description 15
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 15
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
• 230000009258 tissue cross reactivity Effects 0.000 description 14
• 241000283973 Oryctolagus cuniculus Species 0.000 description 13
• 239000003153 chemical reaction reagent Substances 0.000 description 13
• 150000003839 salts Chemical class 0.000 description 13
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 230000002401 inhibitory effect Effects 0.000 description 12
• 230000000813 microbial effect Effects 0.000 description 12
• 235000001014 amino acid Nutrition 0.000 description 11
• 229960003569 hematoporphyrin Drugs 0.000 description 11
• 229940072221 immunoglobulins Drugs 0.000 description 11
• 102000004196 processed proteins & peptides Human genes 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 230000037361 pathway Effects 0.000 description 10
• 238000007539 photo-oxidation reaction Methods 0.000 description 10
• 229920001184 polypeptide Polymers 0.000 description 10
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
• ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 10
• 206010028980 Neoplasm Diseases 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 208000027418 Wounds and injury Diseases 0.000 description 9
• 150000001413 amino acids Chemical class 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 201000011510 cancer Diseases 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 239000000543 intermediate Substances 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 238000002965 ELISA Methods 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 108091008874 T cell receptors Proteins 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 239000011575 calcium Substances 0.000 description 8
• 230000003197 catalytic effect Effects 0.000 description 8
• 230000006378 damage Effects 0.000 description 8
• 238000000502 dialysis Methods 0.000 description 8
• 201000010099 disease Diseases 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 230000036541 health Effects 0.000 description 8
• 210000000987 immune system Anatomy 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 239000010453 quartz Substances 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 230000004083 survival effect Effects 0.000 description 8
• 238000011282 treatment Methods 0.000 description 8
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
• 108010058846 Ovalbumin Proteins 0.000 description 7
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
• 230000000845 anti-microbial effect Effects 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 239000011521 glass Substances 0.000 description 7
• 238000003018 immunoassay Methods 0.000 description 7
• 229940092253 ovalbumin Drugs 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
• 206010057249 Phagocytosis Diseases 0.000 description 6
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
• 102000019197 Superoxide Dismutase Human genes 0.000 description 6
• 108010012715 Superoxide dismutase Proteins 0.000 description 6
• 206010052428 Wound Diseases 0.000 description 6
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 6
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
• 238000004061 bleaching Methods 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 210000002421 cell wall Anatomy 0.000 description 6
• 230000001900 immune effect Effects 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 210000000265 leukocyte Anatomy 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 238000005949 ozonolysis reaction Methods 0.000 description 6
• 230000008782 phagocytosis Effects 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 6
• 229920002554 vinyl polymer Polymers 0.000 description 6
• WGLQHUKCXBXUDV-UHFFFAOYSA-N 3-aminophthalic acid Chemical compound NC1=CC=CC(C(O)=O)=C1C(O)=O WGLQHUKCXBXUDV-UHFFFAOYSA-N 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 241000283707 Capra Species 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 5
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 206010070834 Sensitisation Diseases 0.000 description 5
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 229940098773 bovine serum albumin Drugs 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 230000001332 colony forming effect Effects 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 235000011187 glycerol Nutrition 0.000 description 5
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 230000003053 immunization Effects 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 230000007774 longterm Effects 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 210000001539 phagocyte Anatomy 0.000 description 5
• 210000000680 phagosome Anatomy 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 230000008313 sensitization Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• 241000699800 Cricetinae Species 0.000 description 4
• 238000003775 Density Functional Theory Methods 0.000 description 4
• 241000709661 Enterovirus Species 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• 241000191967 Staphylococcus aureus Species 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000006555 catalytic reaction Methods 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000003814 drug Substances 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 239000010931 gold Substances 0.000 description 4
• 229910052737 gold Inorganic materials 0.000 description 4
• QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 4
• 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 4
• 230000002458 infectious effect Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• 230000003641 microbiacidal effect Effects 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 150000002978 peroxides Chemical class 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 230000001766 physiological effect Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 239000012460 protein solution Substances 0.000 description 4
• 230000005180 public health Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 238000004007 reversed phase HPLC Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 230000007704 transition Effects 0.000 description 4
• 239000003643 water by type Substances 0.000 description 4
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
• 208000035143 Bacterial infection Diseases 0.000 description 3
• 238000004057 DFT-B3LYP calculation Methods 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 241000481005 Escherichia coli O1 Species 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010063837 Reperfusion injury Diseases 0.000 description 3
• 241000607768 Shigella Species 0.000 description 3
• 101710120037 Toxin CcdB Proteins 0.000 description 3
• 108010059993 Vancomycin Proteins 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 3
• 238000002835 absorbance Methods 0.000 description 3
• 238000000862 absorption spectrum Methods 0.000 description 3
• 238000001720 action spectrum Methods 0.000 description 3
• 239000004599 antimicrobial Substances 0.000 description 3
• 125000003118 aryl group Chemical group 0.000 description 3
• 208000022362 bacterial infectious disease Diseases 0.000 description 3
• 230000004888 barrier function Effects 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 230000024203 complement activation Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 238000000354 decomposition reaction Methods 0.000 description 3
• 238000004925 denaturation Methods 0.000 description 3
• 230000036425 denaturation Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 3
• 150000002019 disulfides Chemical class 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 238000000635 electron micrograph Methods 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 150000004665 fatty acids Chemical class 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 238000013467 fragmentation Methods 0.000 description 3
• 238000006062 fragmentation reaction Methods 0.000 description 3
• 238000004108 freeze drying Methods 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 210000003622 mature neutrocyte Anatomy 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 239000000816 peptidomimetic Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 239000003504 photosensitizing agent Substances 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 238000010791 quenching Methods 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000001488 sodium phosphate Substances 0.000 description 3
• 229910000162 sodium phosphate Inorganic materials 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 208000037816 tissue injury Diseases 0.000 description 3
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
• 241001529453 unidentified herpesvirus Species 0.000 description 3
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
• 229960003165 vancomycin Drugs 0.000 description 3
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
• 235000015112 vegetable and seed oil Nutrition 0.000 description 3
• 239000008158 vegetable oil Substances 0.000 description 3
• 230000035899 viability Effects 0.000 description 3
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• PHRHANASDXMZLU-UHFFFAOYSA-N 3-[10-(2-carboxyethyl)anthracen-9-yl]propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=C(C=CC=C3)C3=C(CCC(O)=O)C2=C1 PHRHANASDXMZLU-UHFFFAOYSA-N 0.000 description 2
• QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical compound OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 241000710929 Alphavirus Species 0.000 description 2
• 241000712891 Arenavirus Species 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 241000167854 Bourreria succulenta Species 0.000 description 2
• 241000589513 Burkholderia cepacia Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 241000711573 Coronaviridae Species 0.000 description 2
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 241000194032 Enterococcus faecalis Species 0.000 description 2
• 241000194031 Enterococcus faecium Species 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 241000711950 Filoviridae Species 0.000 description 2
• 241000710831 Flavivirus Species 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 241000589989 Helicobacter Species 0.000 description 2
• 241000590002 Helicobacter pylori Species 0.000 description 2
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 241000700721 Hepatitis B virus Species 0.000 description 2
• 241000709721 Hepatovirus A Species 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 241000712431 Influenza A virus Species 0.000 description 2
• 241000713196 Influenza B virus Species 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• 108090001090 Lectins Proteins 0.000 description 2
• 102000004856 Lectins Human genes 0.000 description 2
• 241000711828 Lyssavirus Species 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 241000712045 Morbillivirus Species 0.000 description 2
• 241000702259 Orbivirus Species 0.000 description 2
• 241000713112 Orthobunyavirus Species 0.000 description 2
• 241000150218 Orthonairovirus Species 0.000 description 2
• 102000004316 Oxidoreductases Human genes 0.000 description 2
• 108090000854 Oxidoreductases Proteins 0.000 description 2
• 229940123973 Oxygen scavenger Drugs 0.000 description 2
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
• 241000282372 Panthera onca Species 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 241000713137 Phlebovirus Species 0.000 description 2
• 241000709664 Picornaviridae Species 0.000 description 2
• 241000711902 Pneumovirus Species 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 241000125945 Protoparvovirus Species 0.000 description 2
• 241000702670 Rotavirus Species 0.000 description 2
• 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 238000001636 atomic emission spectroscopy Methods 0.000 description 2
• 239000003899 bactericide agent Substances 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000029918 bioluminescence Effects 0.000 description 2
• 238000005415 bioluminescence Methods 0.000 description 2
• 210000001772 blood platelet Anatomy 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• PBHVCRIXMXQXPD-UHFFFAOYSA-N chembl2369102 Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(N1)=C1C=2C=CC(=CC=2)S(O)(=O)=O)=C2N=C1C=C2 PBHVCRIXMXQXPD-UHFFFAOYSA-N 0.000 description 2
• 235000019693 cherries Nutrition 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 238000007323 disproportionation reaction Methods 0.000 description 2
• 238000001493 electron microscopy Methods 0.000 description 2
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 229940032049 enterococcus faecalis Drugs 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 150000002211 flavins Chemical class 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 230000004907 flux Effects 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 229940037467 helicobacter pylori Drugs 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 230000028996 humoral immune response Effects 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 230000005934 immune activation Effects 0.000 description 2
• 230000008105 immune reaction Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000001678 irradiating effect Effects 0.000 description 2
• 230000000155 isotopic effect Effects 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
• 239000002523 lectin Substances 0.000 description 2
• 239000007791 liquid phase Substances 0.000 description 2
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 238000009629 microbiological culture Methods 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 208000015380 nutritional deficiency disease Diseases 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 238000007248 oxidative elimination reaction Methods 0.000 description 2
• 238000012856 packing Methods 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 150000004053 quinones Chemical class 0.000 description 2
• 239000000376 reactant Substances 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 238000011946 reduction process Methods 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 230000003252 repetitive effect Effects 0.000 description 2
• HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
• 230000027756 respiratory electron transport chain Effects 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 239000001022 rhodamine dye Substances 0.000 description 2
• 229930187593 rose bengal Natural products 0.000 description 2
• AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 2
• 229940081623 rose bengal Drugs 0.000 description 2
• STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 2
• 238000009738 saturating Methods 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000001235 sensitizing effect Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000009897 systematic effect Effects 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 230000007306 turnover Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000012224 working solution Substances 0.000 description 2
• 238000007106 1,2-cycloaddition reaction Methods 0.000 description 1
• CTFCFOGHHKFCCE-UHFFFAOYSA-N 1-(3,7-dihydroxyphenazin-1-yl)ethanone Chemical compound C(C)(=O)C1=CC(=CC2=NC3=CC(=CC=C3N=C12)O)O CTFCFOGHHKFCCE-UHFFFAOYSA-N 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• CGTBPABRTZFYGD-UHFFFAOYSA-N 3-(oxiran-2-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C2OC2)=C1 CGTBPABRTZFYGD-UHFFFAOYSA-N 0.000 description 1
• UHDNUPHSDMOGCR-UHFFFAOYSA-N 3-Formylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=O)=C1 UHDNUPHSDMOGCR-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical class N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
• VCZAQQDKQNHPDZ-UHFFFAOYSA-N 4-(oxiran-2-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1OC1 VCZAQQDKQNHPDZ-UHFFFAOYSA-N 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000607534 Aeromonas Species 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 241000182988 Assa Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 241001148536 Bacteroides sp. Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 229940122644 Chymotrypsin inhibitor Drugs 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 241000588914 Enterobacter Species 0.000 description 1
• 241000194033 Enterococcus Species 0.000 description 1
• 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010057573 Flavoproteins Proteins 0.000 description 1
• 102000003983 Flavoproteins Human genes 0.000 description 1
• 206010016952 Food poisoning Diseases 0.000 description 1
• 208000019331 Foodborne disease Diseases 0.000 description 1
• 102000020897 Formins Human genes 0.000 description 1
• 108091022623 Formins Proteins 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010022680 Intestinal ischaemia Diseases 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 101710085938 Matrix protein Proteins 0.000 description 1
• 101710127721 Membrane protein Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 101000985214 Mus musculus 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
• 208000029578 Muscle disease Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 241000238367 Mya arenaria Species 0.000 description 1
• 102100030856 Myoglobin Human genes 0.000 description 1
• 108010062374 Myoglobin Proteins 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
• BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 1
• PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 208000031662 Noncommunicable disease Diseases 0.000 description 1
• 241000702244 Orthoreovirus Species 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 241000097929 Porphyria Species 0.000 description 1
• 208000010642 Porphyrias Diseases 0.000 description 1
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 241000710801 Rubivirus Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108010027252 Trypsinogen Proteins 0.000 description 1
• 102000018690 Trypsinogen Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 241000607598 Vibrio Species 0.000 description 1
• 241000726445 Viroids Species 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 239000012082 adaptor molecule Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000005054 agglomeration Methods 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 238000005575 aldol reaction Methods 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
• 150000004056 anthraquinones Chemical class 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 238000005284 basis set Methods 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 150000003935 benzaldehydes Chemical class 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
• 239000007844 bleaching agent Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 238000010504 bond cleavage reaction Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000006189 buccal tablet Substances 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 150000001669 calcium Chemical class 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 230000004856 capillary permeability Effects 0.000 description 1
• 150000005323 carbonate salts Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 230000005465 channeling Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 239000007958 cherry flavor Substances 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 230000002153 concerted effect Effects 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 238000012866 crystallographic experiment Methods 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 230000009849 deactivation Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000008260 defense mechanism Effects 0.000 description 1
• 238000007872 degassing Methods 0.000 description 1
• 230000003413 degradative effect Effects 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 208000001848 dysentery Diseases 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 230000005281 excited state Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000012921 fluorescence analysis Methods 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 125000005908 glyceryl ester group Chemical group 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000000777 hematopoietic system Anatomy 0.000 description 1
• 238000010505 homolytic fission reaction Methods 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 108091006086 inhibitor proteins Proteins 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000005040 ion trap Methods 0.000 description 1
• 208000023589 ischemic disease Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 108010084553 jacalin Proteins 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 238000012792 lyophilization process Methods 0.000 description 1
• 229950002454 lysergide Drugs 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 238000003032 molecular docking Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 244000309711 non-enveloped viruses Species 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000007968 orange flavor Substances 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000004792 oxidative damage Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
• 150000002924 oxiranes Chemical class 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 229940097156 peroxyl Drugs 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000008196 pharmacological composition Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 238000001637 plasma atomic emission spectroscopy Methods 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 210000004896 polypeptide structure Anatomy 0.000 description 1
• 150000004032 porphyrins Chemical class 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003334 potential effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000009993 protective function Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 238000012207 quantitative assay Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 239000000700 radioactive tracer Substances 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000007892 solid unit dosage form Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229910052714 tellurium Inorganic materials 0.000 description 1
• PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
• 238000005979 thermal decomposition reaction Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229910021654 trace metal Inorganic materials 0.000 description 1
• 229910021655 trace metal ion Inorganic materials 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
• 206010061393 typhus Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000009637 wintergreen oil Substances 0.000 description 1
• 150000003736 xenon Chemical class 0.000 description 1
• 238000003868 zero point energy Methods 0.000 description 1